Candel Therapeutics, Inc.

NASDAQ:CADL

Biotechnology

Healthcare
$5.32 +0.56%

+$0.05 today

Market cap
$417.33M
Beta
-0.48
P/E (TTM)
-9.2
EPS (TTM)
-$0.87
52W Low $4.35High $9.57

Volume 1.39M

Average 1.82M

CADL EPS (Diluted)

Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.

Candel Therapeutics, Inc.NASDAQ: CADL

EPS (Diluted) · Q1 FY2026 · quarter ended Mar 2026

EPS (Diluted) turns negative

Q1 FY2026 EPS (Diluted) was -$0.14, compared with $0.23 a year earlier. Trailing-twelve-month EPS (Diluted) was -$0.98.

Context

  • EPS (Diluted) grew in size in 2 of the last 3 fiscal years.

What to watch

Whether EPS (Diluted) reaches the consensus estimate from 5 analysts of -$1.29 (-79.6%) for the fiscal year ending Dec 2026, a slowdown from the +58.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$0.14+74.1% QoQ
Last fiscal yearDec 2025
-$0.72+58.6% YoY
LTMMar 2026
-$0.98+20.7% YoY
EPS (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-160.9%-155.6%+5.3 pp
1 year+58.6%-79.6%-138.2 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EPS (Diluted) history

USD · from the income statement

Latest · FY2025
(0.72) USD
Year-over-year change
+58.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EPS (Diluted) vs competitors

How CADL compares with its peers on the latest reported figures

  • Peers report in different currencies, so EPS (Diluted) is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +20.7% is the 5th highest of 10, against a peer median of +1.1%.
CADL Competitors
EPS (Diluted) for CADL and competitors
Company Period LTM YoY 3-year CAGR
PBYIPuma Biotechnology, Inc.LTM Mar 2026$0.48 USD-37.8%+210.9%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026-$0.53 USD+55.8%—
NBPNovaBridge BiosciencesLTM Sep 2025-CN¥0.62 CNY+87.5%—
GNLXGenelux CorporationLTM Mar 2026-$0.88 USD+1.1%—
IMMXImmix Biopharma, Inc.LTM Mar 2026-$0.92 USD-29.6%—
CADLCandel Therapeutics, Inc.LTM Mar 2026-$0.98 USD+20.7%—
MGNXMacroGenics, Inc.LTM Mar 2026-$1.1 USD-23.6%—
IPSCCentury Therapeutics, Inc.LTM Mar 2026-$1.25 USD-290.6%—
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026-$1.44 USD+23.0%—
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026-$2.8 USD+27.6%—
Peer median (excluding CADL) —+1.1%+210.9%

Competitors are the stored peer set for CADL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue125K125K000
Cost of Revenue00000
Gross Profit125K125K000
Gross Margin100.0%100.0%———
Research & Development15.18M20.79M24.51M19.31M30.5M
Selling, General & Admin10.67M14.06M13.89M14.06M17.77M
Operating Expenses24.78M34.8M38.39M33.37M48.27M
Depreciation & Amortization232K778K960K990K845K
EBITDA(24.42M)(16.31M)(34.38M)(52.1M)(35.22M)
EBITDA Margin-19534.4%-13046.4%———
Operating Income(24.65M)(34.67M)(38.39M)(33.37M)(48.27M)
Operating Margin-19720.0%-27739.2%———
Interest Income01.22M2.08M1.09M3.92M
Interest Expense53K1.71M2.6M2.09M2.12M
Other Income / Expenses(10.4M)15.93M452K(21.81M)10.08M
Income Before Tax(36.12M)(18.79M)(37.94M)(55.18M)(38.18M)
Pre-Tax Margin-28899.2%-15035.2%———
Income Tax Expense00000
Net Income(36.12M)(18.79M)(37.94M)(55.18M)(38.18M)
Net Margin-28899.2%-15035.2%———
EPS (Basic)(1.26)(0.10)(1.31)(1.74)(0.72)
EPS (Diluted)(1.26)(0.10)(1.31)(1.74)(0.72)
Weighted Avg Shares28.69M28.82M28.94M31.68M52.96M
Weighted Avg Shares (Diluted)28.69M28.82M28.94M31.68M52.96M

Candel Therapeutics, Inc.

NASDAQ:CADL

Intrinsic Alpha fair value

Locked

Current Price

$5.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.